Related Experiment Video
Updated: Jul 10, 2026
09:03
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
Published on: June 19, 2018
Evaluating a surrogate endpoint at three levels, with application to vaccine development
Peter B Gilbert1, Li Qin, Steven G Self
1Fred Hutchinson Cancer Research Center and Department of Biostatistics, University of Washington, Seattle, WA 98109, USA. pgilbert@scharp.org
Statistics in Medicine
|November 6, 2007
Summary
Developing a reliable immune response marker for vaccine protection is crucial. This study outlines three criteria and statistical methods to validate immunological surrogate endpoints for predicting vaccine efficacy across diverse settings.
Area of Science:
- Vaccinology
- Immunology
- Biostatistics
Background:
- Identifying reliable immunological surrogate endpoints is vital for vaccine research and development.
- Surrogate endpoints aim to predict clinical protection from infection, accelerating vaccine evaluation.
Purpose of the Study:
- To propose a hierarchy of three criteria for validating immunological surrogate endpoints.
- To present statistical frameworks for evaluating these surrogate endpoints.
- To illustrate the application of these criteria and frameworks using vaccine trial data.
Main Methods:
- Assessing correlation between immune response and clinical endpoints in vaccine trials.
- Evaluating surrogate potential for predicting vaccine efficacy in similar settings.
- Utilizing meta-analysis for external validation of surrogate endpoints across new settings.
- Employing simulated and real-world vaccine trial data for illustration.
Main Results:
- Demonstrated a three-level hierarchy for surrogate endpoint validation.
- Showcased the utility of baseline covariates, study design, and potential outcomes in assessment.
- Provided an example where anti-influenza antibody levels serve as a strong surrogate.
- Provided an example where anti-HIV antibody levels are not a useful surrogate.
Conclusions:
- Established a rigorous framework for validating immunological surrogate endpoints.
- Highlighted the context-dependent nature of surrogate endpoint validity.
- Emphasized the importance of meta-analysis for generalizability and building predictive bridges for vaccine efficacy.
More Related Videos
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...